---
title: "Sanofi-Aventis Deutschland GmbH and others v Amgen Inc. (UPC CoA 320/2023, 13-10-2023)"
description: "A statement of claim can be validly served without its annexes, so the deadlines for the preliminary objection and the statement of defence run from service."
url: https://pitch.law/academy/upc-court-of-appeal/upc-coa-320-2023-2023-10-13
lang: en
author: "UPC Case Law by Pitch"
editor: "Bart Lieben"
datePublished: 2026-11-18T10:07:09.356Z
dateModified: 2026-11-18T10:07:09.356Z
---

# Sanofi-Aventis Deutschland GmbH and others v Amgen Inc.

Order of the UPC Court of Appeal of 13 October 2023, UPC CoA 320/2023.

UPC Case Law by Pitch, edited by [Bart Lieben](https://pitch.law/team/bart-lieben) · Published 18-11-2026

## TL;DR

A statement of claim can be validly served without its annexes, so the deadlines for the preliminary objection and the statement of defence run from service. But if the claimant breaches R 13.2 RoP by not uploading the annexes to the CMS together with the claim, the defendant's extension request must be granted, whatever the annexes contain. The extension normally equals the period the annexes were missing, so the claimant bears the cost of late annexes.

## Key holding

Under R 271 RoP, read in light of Regulation (EU) 2020/1784 via Art 24(1)(a) UPCA, a statement of claim referring to or announcing annexes is validly served without them if it enables the defendant to assert its rights, in particular by stating with certainty the subject matter and cause of action. R 13.2 RoP requires the annexes to be uploaded to the CMS at the same time as the statement of claim. Where they were not, and were therefore unavailable when the defendant's representative accessed the CMS, a defendant's request to extend the time limits under R 19.1 and R 23 RoP must be granted, regardless of the nature or content of the annexes. Unless the claimant shows special circumstances, the extension equals the period of unavailability.

## Questions decided

1. Is a statement of claim validly served under R 271 RoP without its annexes?
2. Do the R 19.1 and R 23 RoP time limits run from service of the claim or from upload of the annexes?
3. Does R 13.2 RoP require annexes to be uploaded at the same time as the statement of claim?
4. Does late upload of annexes in itself justify extending the time limits, whatever their content?
5. How long should the extension be, and who must show special circumstances?

## Case details

- Court: Court of Appeal of the Unified Patent Court, Second Panel
- Panel: Rian Kalden (presiding judge and judge-rapporteur); Ingeborg Simonsson (legally qualified judge); Patricia Rombach (legally qualified judge)
- Date: 13-10-2023
- Case number(s): UPC CoA 320/2023, UPC CFI 14/2023
- Parties: Appellants: Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis Groupe S.A., Sanofi Winthrop Industrie S.A. and Regeneron Pharmaceuticals Inc. (defendants at first instance); Respondent: Amgen Inc. (claimant at first instance)
- Language of the proceedings: German (oral hearing held in English)
- Outcome: The Court of Appeal set aside the order of 29 August 2023. It ordered that the time limits for the preliminary objection and the statement of defence in UPC CFI 14/2023 (ACT_459916/2023) be extended and end, for all appellants, on 11 September and 10 November 2023 respectively.

## How to cite

Court of Appeal, Sanofi-Aventis Deutschland GmbH and others v Amgen Inc., UPC CoA 320/2023, Order of 13 October 2023 (OSCOLA)

## Full summary

Read the full analyses for free — create a free account: https://pitch.law/academy/upc-court-of-appeal/upc-coa-320-2023-2023-10-13

Topics: [Jurisdiction and competence](https://pitch.law/academy/upc-court-of-appeal/topics/jurisdiction), [Procedure](https://pitch.law/academy/upc-court-of-appeal/topics/procedure)

## In the same case

- [Amgen, Inc v Sanofi-Aventis Deutschland GmbH and others, UPC CoA 528/2024, 25-11-2025](https://pitch.law/academy/upc-court-of-appeal/upc-coa-528-2024-2025-11-25): The Court of Appeal overturned the Munich central division and upheld Amgen's PCSK9 antibody patent EP 3 666 797 against Sanofi and Regeneron, finding that the skilled person had no reasonable expectation of success that an antibody would be therapeutically effective.

## More on jurisdiction and competence

- [Hurom Co., Ltd. v NUC Electronics Co., Ltd and others, UPC CoA 678/2025, 28-08-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-678-2025-2026-08-28): The Court of Appeal upheld the Paris Local Division's revocation of Hurom's juicer patent EP 3 155 936 (as amended) for lack of inventive step, refused Hurom's new auxiliary requests filed only on appeal, and confirmed dismissal of all infringement claims, including those for Poland.
- [Knaus Tabbert AG v Yellow Sphere Innovations GmbH and others, UPC CoA 365/2025, 17-08-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-365-2025-2026-08-17): The Court of Appeal dismissed Knaus Tabbert's appeals and upheld the Düsseldorf Local Division's finding that its caravan frames infringe EP 3 356 109, which remains valid.
- [Fujifilm Corporation v Kodak GmbH and others, UPC CoA 473/2025, 13-07-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-473-2025-2026-07-13): The Court of Appeal reversed the Mannheim Local Division and held Fujifilm's lithographic printing plate patent (EP 3 476 616, as centrally limited) valid and infringed by Kodak's Sonora plates in Germany, granting an injunction, damages, information, recall and destruction.
- [Rematec GmbH & Co KG v Europe Forestry B.V., UPC CoA 302/2025, 03-07-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-302-2025-2026-07-03): The Court of Appeal confirmed that an application for a cost decision under R 151 RoP must be filed with the Court of First Instance, even where it concerns only or partly the costs of the appeal.
- [SILIMED Indústria de Implantes Ltda (re opt-out of EP 2 581 193 filed by Polytech Health&Aesthetics GmbH), UPC CoA 66/2026, 29-06-2026](https://pitch.law/academy/upc-court-of-appeal/upc-coa-66-2026-2026-06-29): The President of the Court of Appeal rejected an application to review the Registrar's refusal to remove an opt-out as unauthorised under R 5A RoP.
